Article Text

Download PDFPDF
Early-stage Burkitt lymphoma remained in remission 7 years from diagnosis after only one cycle of chemoimmunotherapy
  1. Ali Al Sbihi1,
  2. Nouraldeen Manasrah1,
  3. Dahlia Sano2 and
  4. Sarah Lonardo3
  1. 1Internal Medicine, Sinai Grace Hospital, Detroit, Michigan, USA
  2. 2Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
  3. 3Hematopathology, Harper University Hospital, Detroit, Michigan, USA
  1. Correspondence to Dr Ali Al Sbihi; aalsbihi{at}dmc.org

Abstract

Burkitt lymphoma (BL) is a rare, mature, fast-growing and highly aggressive B-cell neoplasm. It has a high-proliferation rate with distinctive genetic changes in the C-MYC oncogene. Treatment usually requires intense and frequent chemotherapy regimens with central nervous system prophylaxis as the usual regimens used for other non-Hodgkin’s lymphoma yield poor survival in BL. This report discusses a patient who was diagnosed with a stage II, high-grade BL who received one cycle of intense chemotherapy and refused further treatment. That patient remained in complete remission in his last follow-up; 7 years from diagnosis without requiring other therapies for his lymphoma.

  • oncology
  • cancer intervention
  • haematology (incl blood transfusion)
  • head and neck cancer

Statistics from Altmetric.com

Footnotes

  • Contributors AAS: primary author: interviewed and got the patient’s consent, wrote the manuscript with a detailed literature review, provided most of the contribution to the revised manuscript. NM: helped in writing and finalising the manuscript especially with the initial proofreading. DS: haematology/oncology attending who was the main physician on the patient’s case, did the final and detailed revision of the manuscript on both revisions. SL: read the pathology slides and helped in choosing the best description of the slides’ in the manuscript based on the biopsy.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.